Drug firms donate compounds for anti-HIV gel.
Towie
Narelle
N
D000282:Administration, Intravaginal; D000349:Africa; D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000191:economics* / Q000494:pharmacology; D002986:Clinical Trials as Topic / Q000639:trends; D004345:Drug Industry; D004359:Drug Therapy, Combination; D005260:Female; D005782:Gels / Q000008:administration & dosage* / Q000737:chemistry; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000191:economics / Q000494:pharmacology; D011720:Pyrazoles / Q000008:administration & dosage / Q000191:economics / Q000494:pharmacology; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000191:economics / Q000494:pharmacology
D019380:Anti-HIV Agents; C477855:BMS-378806; C480490:CMPD 167; D005782:Gels; D010879:Piperazines; D011720:Pyrazoles; D014633:Valine